Home › Acute Myeloid Leukemia
Acute Myeloid Leukemia clinical trials recruiting in the U.S.
276 studies for Acute Myeloid Leukemia are recruiting participants at sites across the United States.
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.
Cities with the most studies
- Houston, TX85 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Baldwin Park, CA40 studies
- Seattle, WA40 studies
- Columbus, OH35 studies
- Philadelphia, PA34 studies
- Durham, NC33 studies
- Atlanta, GA30 studies
- Tampa, FL29 studies
- Chicago, IL26 studies
- Portland, OR25 studies
- Miami, FL24 studies
- Washington, DC24 studies
- Los Angeles, CA24 studies
- St. Louis, MO22 studies
- Dallas, TX21 studies
- Birmingham, AL21 studies
- Nashville, TN21 studies
- Queens, NY21 studies
- Cincinnati, OH20 studies
- Cleveland, OH20 studies
- Edison, NJ20 studies
- Minneapolis, MN20 studies
- Buffalo, NY19 studies
- Mountain View, CA19 studies
- Baltimore, MD19 studies
- Winston-Salem, NC18 studies
- Pittsburgh, PA18 studies
- Greenburgh, NY18 studies
- Salt Lake City, UT17 studies
- Ann Arbor, MI17 studies
- Milwaukee, WI17 studies
- New Haven, CT17 studies
- Rochester, NY16 studies
- Aurora, CO16 studies
- Charlotte, NC16 studies
- Charlottesville, VA16 studies
- Madison, WI16 studies
- Cedar Rapids, IA16 studies
By state
- Alabama21 studies
- Arizona22 studies
- Arkansas13 studies
- California79 studies
- Colorado22 studies
- Connecticut17 studies
- Delaware7 studies
- District of Columbia10 studies
- Florida55 studies
- Georgia38 studies
- Hawaii7 studies
- Idaho9 studies
- Illinois31 studies
- Indiana14 studies
- Iowa17 studies
- Kansas20 studies
- Kentucky14 studies
- Louisiana13 studies
- Maine9 studies
- Maryland31 studies
- Massachusetts45 studies
- Michigan24 studies
- Minnesota27 studies
- Mississippi8 studies
- Missouri23 studies
- Montana6 studies
- Nebraska10 studies
- Nevada9 studies
- New Hampshire9 studies
- New Jersey32 studies
- New Mexico9 studies
- New York71 studies
- North Carolina43 studies
- North Dakota4 studies
- Ohio57 studies
- Oklahoma14 studies
- Oregon27 studies
- Pennsylvania45 studies
- Rhode Island11 studies
- South Carolina16 studies
- South Dakota6 studies
- Tennessee31 studies
- Texas94 studies
- Utah17 studies
- Vermont7 studies
- Virginia24 studies
- Washington41 studies
- West Virginia6 studies
- Wisconsin25 studies
Recently updated studies
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07581002Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Oct 2, 2026 · NCT07437950Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07304011Assessment of Geriatric Evaluations Impact on New AML Guidance
RecruitingObservational study
Ages 50 and older · All sexes · Updated Oct 2, 2026 · NCT05909501Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Oct 2, 2026 · NCT06904066Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07723703Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06484062Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 1, 2026 · NCT06131801A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RecruitingPhase 1
Ages 12 to 78 · All sexes · Updated Sep 29, 2026 · NCT03802695A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06763341Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Sep 28, 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT03629171A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06548230Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 25, 2026 · NCT07211958Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT03874052Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06398457Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT03661307Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06871410A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
RecruitingPhase 1/2Healthy volunteers welcome
Ages 12 and older · All sexes · Updated Sep 23, 2026 · NCT05360160A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
RecruitingPhase 1
Up to age 21 · All sexes · Updated Sep 23, 2026 · NCT07012044Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06317649A Study of CRD3874-SI in People With Leukemia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07661095From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.